Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Phys Rev Lett ; 121(24): 242501, 2018 Dec 14.
Artigo em Inglês | MEDLINE | ID: mdl-30608744

RESUMO

The isospin character of p-n pairs at large relative momentum has been observed for the first time in the ^{16}O ground state. A strong population of the J,T=1,0 state and a very weak population of the J,T=0,1 state were observed in the neutron pickup domain of ^{16}O(p,pd) at 392 MeV. This strong isospin dependence at large momentum transfer is not reproduced by the distorted-wave impulse approximation calculations with known spectroscopic amplitudes. The results indicate the presence of high-momentum protons and neutrons induced by the tensor interactions in the ground state of ^{16}O.

2.
Phys Rev Lett ; 118(5): 052701, 2017 Feb 03.
Artigo em Inglês | MEDLINE | ID: mdl-28211732

RESUMO

The cross sections of the ^{7}Be(n,α)^{4}He reaction for p-wave neutrons were experimentally determined at E_{c.m.}=0.20-0.81 MeV slightly above the big bang nucleosynthesis (BBN) energy window for the first time on the basis of the detailed balance principle by measuring the time-reverse reaction. The obtained cross sections are much larger than the cross sections for s-wave neutrons inferred from the recent measurement at the n_TOF facility in CERN, but significantly smaller than the theoretical estimation widely used in the BBN calculations. The present results suggest the ^{7}Be(n,α)^{4}He reaction rate is not large enough to solve the cosmological lithium problem, and this conclusion agrees with the recent result from the direct measurement of the s-wave cross sections using a low-energy neutron beam and the evaluated nuclear data library ENDF/B-VII.1.

3.
Biol Pharm Bull ; 16(11): 1083-6, 1993 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8312859

RESUMO

S-(1,2-Dicarboxyethyl)glutathione (DCE-GS) in addition to being present in the liver, lens, and heart, also inhibited platelet aggregation. To clarify these inhibitory effects, the role of DCE-GS in the release of ATP and serotonin from platelets was studied, as was thromoboxane A2 formation, cyclic AMP level and adenylate cyclase activity in human platelets. The results are as follows: DCE-GS at a concentration of 1.3 mM inhibited ATP and serotonin release from platelets induced by collagen, by 77.4 +/- 4.3 and 78.7 +/- 6.3%, respectively. At 1.5 mM DCE-GS also inhibited the formation of thromboxane B2 by 79.6 +/- 4.1%. Incubation of human platelet rich plasma with 2 mM of DCE-GS for 10 min increased the cyclic AMP level and the activity of adenylate cyclase by 204 +/- 28 and 211 +/- 11.7%, respectively. These results suggest that the inhibitory effect of DCE-GS on the platelet aggregation induced by collagen is due to an increase in the cyclic AMP level in platelets, which in turn may be due to enhancement of the activity of adenylate cyclase.


Assuntos
Plaquetas/efeitos dos fármacos , AMP Cíclico/sangue , Glutationa/análogos & derivados , Inibidores da Agregação Plaquetária/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Trifosfato de Adenosina/sangue , Adenilil Ciclases/sangue , Plaquetas/enzimologia , Plaquetas/metabolismo , Colágeno/farmacologia , Glutationa/farmacologia , Humanos , Masculino , Serotonina/sangue , Tromboxano A2/biossíntese
4.
Int J Clin Pharmacol Ther Toxicol ; 31(2): 83-8, 1993 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8458681

RESUMO

The effects of SQ29,852 (n = 24), a new angiotensin converting enzyme inhibitor, and atenolol (n = 22), monotherapies were compared in 46 patients with mild to moderate essential hypertension. Both SQ29,852 (mean dose 15.0 +/- 5.1 mg/day) and atenolol (mean dose 37.5 +/- 18.5 mg/day) significantly decreased both systolic and diastolic blood pressures. There were no significant changes in serum lipids, apolipoproteins, lipoproteins or atherosclerotic indices after both SQ29,852 and atenolol. There were also no significant inter-group differences. There were no serious side effects or abnormal laboratory tests in both treatment groups. It is concluded that SQ29,852 is an effective antihypertensive drug without adverse effect on lipid metabolism.


Assuntos
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Atenolol/uso terapêutico , Hipertensão/tratamento farmacológico , Lipídeos/sangue , Compostos Organofosforados/uso terapêutico , Prolina/análogos & derivados , Adulto , Idoso , Análise de Variância , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Apolipoproteínas/sangue , Arteriosclerose/sangue , Arteriosclerose/tratamento farmacológico , Atenolol/efeitos adversos , Pressão Sanguínea/efeitos dos fármacos , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Hipertensão/fisiopatologia , Lipoproteínas/sangue , Masculino , Pessoa de Meia-Idade , Compostos Organofosforados/efeitos adversos , Fosfatidilcolina-Esterol O-Aciltransferase/sangue , Prolina/efeitos adversos , Prolina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA